Traditional Chinese medicine and epigenetics: an ethnopharmacological review of botanical drugs and plant metabolites

Epigenetic mechanisms—DNA methylation, histone modifications, non-coding RNA activity, N6-methyladenosine (m6A) RNA modification and ATP-dependent chromatin remodelling—regulate gene expression without altering the underlying DNA sequence, and they respond to environmental and pharmacological stimuli. Traditional Chinese Medicine (TCM) selects multi-botanical-drug preparations according to syndrome patterns (zheng) rather than biomedical disease categories, and epigenetics has been proposed as a framework within which the action of such preparations might be examined. We reviewed the literature as two related but distinct evidence streams: 76 study-level reports covering 59 distinct interventions, comprising 26 multi-botanical-drug formulas, seven extracts of a single botanical drug, one metabolite–botanical drug combination, 41 isolated plant metabolites or metabolite mixtures, and one derived peptide. Because ConPhyMP addresses plant material and its extracts, we applied it only to the 34 botanical-drug preparations, and audited the isolated metabolites separately for provenance and for specificity to the Chinese materia medica. Botanical authentication, drug-to-extract ratios, chromatographic fingerprints and marker-metabolite quantification were available for a minority of the 34 preparations, and no study compared two batches of the same preparation. On a nine-level evidence scale, 59 of 76 reports reached grade 5 (perturbational dependence) and one reached grade 9 (randomised trial); none reached grade 6, at which an epigenetic change is shown to mediate a phenotypic effect. Six of the most frequently studied metabolites—curcumin, resveratrol, epigallocatechin-3-gallate, quercetin, luteolin and kaempferol—are major metabolites of cosmopolitan food plants, which limits how far their effects can be generalised to TCM practice. Epigenetics remains a plausible and testable framework for TCM botanical drugs, and advancing it will depend on ConPhyMP-compliant reporting and on formula-level designs that can compare a preparation with its individual metabolites.

Authors

Institutions

Publication Details

Journal
Frontiers in Pharmacology
Published
2026-11-16
DOI
https://doi.org/10.3389/fphar.2026.1973612
Primary Topic
Epigenetics and DNA Methylation
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Traditional Chinese medicine and epigenetics: an ethnopharmacological review of botanical drugs and plant metabolites

Qi Li, Haoyu Chen, Hangyu Chen, Yangang Wang et al.
2 links
Frontiers in Pharmacology
Epigenetics and DNA Methylation
article

Traditional Chinese medicine and epigenetics: an ethnopharmacological review of botanical drugs and plant metabolites

Qi Li, Haoyu Chen, Hangyu Chen, Yangang Wang, Jian Lin
article en

Abstract

Epigenetic mechanisms—DNA methylation, histone modifications, non-coding RNA activity, N6-methyladenosine (m6A) RNA modification and ATP-dependent chromatin remodelling—regulate gene expression without altering the underlying DNA sequence, and they respond to environmental and pharmacological stimuli. Traditional Chinese Medicine (TCM) selects multi-botanical-drug preparations according to syndrome patterns (zheng) rather than biomedical disease categories, and epigenetics has been proposed as a framework within which the action of such preparations might be examined. We reviewed the literature as two related but distinct evidence streams: 76 study-level reports covering 59 distinct interventions, comprising 26 multi-botanical-drug formulas, seven extracts of a single botanical drug, one metabolite–botanical drug combination, 41 isolated plant metabolites or metabolite mixtures, and one derived peptide. Because ConPhyMP addresses plant material and its extracts, we applied it only to the 34 botanical-drug preparations, and audited the isolated metabolites separately for provenance and for specificity to the Chinese materia medica. Botanical authentication, drug-to-extract ratios, chromatographic fingerprints and marker-metabolite quantification were available for a minority of the 34 preparations, and no study compared two batches of the same preparation. On a nine-level evidence scale, 59 of 76 reports reached grade 5 (perturbational dependence) and one reached grade 9 (randomised trial); none reached grade 6, at which an epigenetic change is shown to mediate a phenotypic effect. Six of the most frequently studied metabolites—curcumin, resveratrol, epigallocatechin-3-gallate, quercetin, luteolin and kaempferol—are major metabolites of cosmopolitan food plants, which limits how far their effects can be generalised to TCM practice. Epigenetics remains a plausible and testable framework for TCM botanical drugs, and advancing it will depend on ConPhyMP-compliant reporting and on formula-level designs that can compare a preparation with its individual metabolites.

Frontiers in PharmacologyVol. 17
Beijing University of Chinese Medicine (CN), Peking University (CN), Hainan University (CN), Beijing National Laboratory for Molecular Sciences (CN), Hebei University of Chinese Medicine (CN), Peking University Third Hospital (CN)
National Natural Science Foundation of China, Beijing University of Chinese Medicine
Good health and well-being
Epigenetics and DNA Methylation
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon